Chinese herbal medicine is a viable treatment for almost all cancers

Australia's University of Western Sydney and Beijing University of Chinese Medicine recently conducted a large, retrospective review of thousands of studies and "hundreds of thousands of cancer patients" which proved that Chinese herbal medicine is indeed a viable treatment for almost all cancers.

The researchers intensely scrutinized lung, liver, stomach, breast, esophageal, colorectal and nasopharyngeal (throat and sinus) cancer. Breast cancer was the fourth most studied of all the cancers. The researchers analyzed and reviewed 2,964 human clinical studies that involved 253,434 mostly cancer patients. Among these were 2,385 randomized, controlled studies and 579 non-randomized, controlled studies.

In 90% of the clinical studies, Chinese herbal medicine was used. However, 72% of these cases used a combination of conventional allopathic treatment and Traditional Chinese Medicine (TCM). The remaining 28% used TCM exclusively and were considered experimental.

Among cancer patients, 64% were treated with a combination of conventional allopathic cancer treatment and TCM. The remaining cancer patients received TCM exclusively. However, roughly half of those patients (TCM only) had received allopathic cancer treatment in the past.

In the United States, acupuncture is frequently used merely adjunctively to alleviate pain and other side effects caused by cancer and the allopathic cancer treatments used to treat it. In contrast, China can rely on TCM as their conventional therapy for cancer.

Due to the sheer volume of the study, the results were understandably diverse based on these variables: type of study, type of treatment and the specific outcomes for which the researchers were testing.

Nevertheless, the TCM results were impressively undeniable. Based on 1,015 studies, a whopping 85% of the participants reported a decrease in cancer symptoms, especially pain. Significantly, an additional 883 studies exhibited a 70% increase in survival rates, as well as a 38% reduction in tumor size, a 28% improvement in quality of life, a 19% reduction in relapse and, finally, a 7% reduction in complications.